Thursday, November 21, 2024
11/21/2024
PROJECT SUMMARY/ABSTRACT Cancer is a common diagnosis in the emergency department (ED) and by the time patients reach the ED, their cancer has often progressed to later stages. EDs are not intended to diagnose cancer. Training in cancer management is limited for ED physicians, and patient access to follow-up care after a visit to the ED is often difficult. Research from other western countries tells us that, compared to non-emergency settings, cancer diagnosis through the ED is an independent predictor for worse outcomes, including poorer overall survival. Very little is known about emergency diagnosis of cancer in the United States (U.S.). From a handful of studies conducted in a few cancer types, we know that up to 30% of cancer patients are diagnosed as emergencies, and low income and racial/ethnic minority patients are substantially more likely to be affected. However, across different cancer types, the burden and risk factors of cancer diagnosis as an emergency have not been studied. Furthermore, no population-based studies in the U.S. have compared survival differences in patients with cancers diagnosed in EDs vs other non-emergent settings. And among those who are diagnosed as emergencies, it is unclear why they visited the ED, rather than going to a primary care provider for their diagnosis. Our long term goal is to establish the epidemiology of emergency cancer diagnosis in the U.S. We will describe the burden of cancer diagnosis in the emergency department including the patient characteristics of those most affected and quantify disparities across vulnerable populations defined by socioeconomic status, race/ethnicity, and geographic isolation (Aim 1). We will estimate the relative importance of ED (compared to non-ED) diagnosis on patient survival, after controlling for known risk factors like cancer stage, treatment, patient age and chronic conditions (Aim 2). Finally, we will investigate modifiable drivers of disparities among patients diagnosed as emergencies by examining their pre- and post-diagnostic patterns of care to identify opportunities for prevention and improved outcomes (Aim 3). Our highly efficient study design uses epidemiologic methods to analyze high-quality, population-based SEER-Medicare data for 1.8 million, Americans who were diagnosed cancers of the esophagus, stomach, colon/rectum, liver, pancreas, lung, breast, uterus, ovary, prostate, bladder, kidney, non-Hodgkin’s lymphoma, myeloma, and leukemia. The investigative team includes experts in cancer epidemiology, healthcare delivery, cancer health disparities, medical sociology, and oncology, family, and emergency medicine. This will be the first large-scale study of emergency cancer diagnosis in the U.S. Establishing a base of evidence about this important problem, including who is affected, where, and why, will illuminate a largely unrecognized issue, and identify modifiable drivers of disparities in patients with the poorest prognoses.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
